Main > > >COMPANION DIAGNOSTICS. (ONCO.). *

---

Colon Cancer>Companion Diagnostics.
"Biopsy>Liquid Biopsy CTCs+ctDNA"
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2018. 06.12.




Leukemia>Acute Myeloid Leukemia>FLT3 Mutation+
EU Approval Date: 2019. 12.05.
JP Approval Date: 2019. 06.19.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.22.




Solid Tumors. BioMarker Platform>>
>Measures Phosphorylated Proteins>
in tumor tissue. Phosphorylated
proteins represent active targets for
drugs.
>Uses RPPA Technology>
to measure the quantity, activity and
downstream signaling pathway activation
levels for receptors of FDA-approved
and investigational drugs in order to
determine whether or not a prescribed
medication is likely to be effective in
treating the cancer of a specific
patient at that moment in time.
This highly sensitive analysis empowers
physicians to make better treatment
decisions by giving a greater degree of
certainty as to whether a specific drug
will work in treating a specific
patient, as well as informing a
physician whether a chemotherapy
treatment is unlikely to be effective.
This information potentially allows the
patient to forego the devastating side
effects of cytotoxic treatments that
are unlikely to deliver clinically
meaningful benefit, while guiding
physicians to prescribing treatments
likely to yield maximum benefit.
RPPA: reverse phase protein array.
Solid Tumors: Breast; Colon; Pancreatic.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.21.




Solid Tumors. Drug Response Predictor.
mRNA-Based.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 10.21.




Solid Tumors. Genomic Profiling Test.
USA Approval Date: 2017. 11.30.
USA Launch Date : 2018. 03.30.
(*) Company : Foundation Medicine.
TradeMark: FoundationOne CDx™




Solid Tumors. Oncomine Dx Target Test.
BioMarkers: EGFR, BRAF, KRAS and ERBB2 mutations, as well as ALK, ROS1, RET, NTRK and MET fusions. It is also validated as a companion diagnostic (CDx) for approved therapies in non-small cell lung cancer (NSCLC), including ALK, ROS1 and BRAF kinase inhibitors, as well as EGFR exon 19 deletions and L858R tyrosine kinase inhibitors.
EU Approval Date: 2018. 10.17.
(*) Company: Thermo Fisher Scientific.
UpDate: 2018. 10.21.




Solid Tumors. Overall Tumor Mutation Burden (TMB) Platform>Whole Exome
Sequencing.
USA Approval Date: 2019. 11.12.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 01.03.



>COMPANION DIAGNOSTICS. (ONCO.). *'s products
This section has no products